Transcode Therapeutics (RNAZ) Other Non-Current Liabilities (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Other Non-Current Liabilities came in at $6.8 million in Q1 2026, up 1636.67% YoY from $392000.0 in Q1 2025, and up 6.97% on a QoQ basis from $6.4 million in Q4 2025.
Transcode Therapeutics (RNAZ) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Other Non-Current Liabilities data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 1636.67% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 1636.67% YoY) and the FY2025 annual result came in at $6.4 million, down 2.71% from the prior year.
- Other Non-Current Liabilities grew to $6.8 million in Q1 2026, from $6.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $6.8 million in Q1 2026 to a low of $353000.0 in Q4 2023.
- A 4-year average of $3.1 million and a median of $832875.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 1753.09% — and 2025, when it fell 2.71%.
- Tracing RNAZ's Other Non-Current Liabilities over 4 years: stood at $353000.0 in 2023, then jumped by 1753.09% to $6.5 million in 2024, then dropped by 2.71% to $6.4 million in 2025, then climbed by 6.97% to $6.8 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $6.8 million (Q1 2026), $6.4 million (Q4 2025), and $832875.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Mn |
| Dec 31, 2025 | 6.36 Mn |
| Sep 30, 2025 | 832,875.00 |
| Jun 30, 2025 | 553,714.00 |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 353,000.00 |
| Jun 30, 2021 | 2.65 Mn |
| Dec 31, 2020 | 1.78 Mn |